NEXGEL, Inc. (NXGL)
USD 2.84
(-1.45%)
USD 2.84
(-1.45%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.31 Million USD | 162.75% |
| 2022 | 502 Thousand USD | 72.51% |
| 2021 | 291 Thousand USD | 24.89% |
| 2020 | 233 Thousand USD | 106.19% |
| 2019 | 113 Thousand USD | 11.88% |
| 2018 | 101 Thousand USD | 8.6% |
| 2017 | 93 Thousand USD | -41.14% |
| 2016 | 158 Thousand USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 1.44 Million USD | 5.62% |
| 2024 Q1 | 1.36 Million USD | 3.79% |
| 2023 Q4 | 1.31 Million USD | 21.01% |
| 2023 FY | 1.31 Million USD | 162.75% |
| 2023 Q3 | 1.09 Million USD | 1.02% |
| 2023 Q1 | 968 Thousand USD | 92.83% |
| 2023 Q2 | 1.07 Million USD | 11.47% |
| 2022 Q2 | 381 Thousand USD | 36.07% |
| 2022 Q3 | 399 Thousand USD | 4.72% |
| 2022 Q1 | 280 Thousand USD | -3.78% |
| 2022 FY | 502 Thousand USD | 72.51% |
| 2022 Q4 | 502 Thousand USD | 25.81% |
| 2021 Q4 | 291 Thousand USD | 11.49% |
| 2021 FY | 291 Thousand USD | 24.89% |
| 2021 Q3 | 261 Thousand USD | 15.49% |
| 2021 Q2 | 226 Thousand USD | -10.32% |
| 2021 Q1 | 252 Thousand USD | 8.15% |
| 2020 Q2 | 168 Thousand USD | 35.48% |
| 2020 Q1 | 124 Thousand USD | 9.73% |
| 2020 FY | 233 Thousand USD | 106.19% |
| 2020 Q4 | 233 Thousand USD | 48.41% |
| 2020 Q3 | 157 Thousand USD | -6.55% |
| 2019 Q4 | 113 Thousand USD | 0.0% |
| 2019 Q3 | 113 Thousand USD | -19.29% |
| 2019 FY | 113 Thousand USD | 11.88% |
| 2019 Q2 | 140 Thousand USD | 27.27% |
| 2019 Q1 | 110 Thousand USD | 8.91% |
| 2018 FY | 101 Thousand USD | 8.6% |
| 2018 Q3 | 183 Thousand USD | 0.0% |
| 2018 Q4 | 101 Thousand USD | -44.81% |
| 2018 Q1 | - USD | -100.0% |
| 2017 Q4 | 93 Thousand USD | 0.0% |
| 2017 FY | 93 Thousand USD | -41.14% |
| 2016 FY | 158 Thousand USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 17.87 Million USD | 92.622% |
| AngioDynamics, Inc. | 60.61 Million USD | 97.824% |
| AtriCure, Inc. | 67.89 Million USD | 98.057% |
| Avinger, Inc. | 5.29 Million USD | 75.104% |
| Azenta, Inc. | 128.19 Million USD | 98.971% |
| BioLife Solutions, Inc. | 43.45 Million USD | 96.965% |
| The Cooper Companies, Inc. | 735.6 Million USD | 99.821% |
| Daxor Corporation | - USD | -Infinity% |
| Ekso Bionics Holdings, Inc. | 5.05 Million USD | 73.881% |
| Femasys Inc. | 667.11 Thousand USD | -97.716% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 24.71 Million USD | 94.663% |
| Hologic, Inc. | 679.8 Million USD | 99.806% |
| ICU Medical, Inc. | 709.36 Million USD | 99.814% |
| Intuitive Surgical, Inc. | 1.22 Billion USD | 99.892% |
| KORU Medical Systems, Inc. | 3.48 Million USD | 62.112% |
| LeMaitre Vascular, Inc. | 52.33 Million USD | 97.48% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -53.952% |
| Innovative Eyewear, Inc. | 856.75 Thousand USD | -53.952% |
| Masimo Corporation | 545 Million USD | 99.758% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 1.61 Million USD | 18.441% |
| Merit Medical Systems, Inc. | 303.87 Million USD | 99.566% |
| Nephros, Inc. | 2.47 Million USD | 46.599% |
| NovoCure Limited | 38.15 Million USD | 96.543% |
| NEXGEL, Inc. | 1.31 Million USD | 0.0% |
| Singular Genomics Systems, Inc. | 13.57 Million USD | 90.281% |
| OraSure Technologies, Inc. | 47.61 Million USD | 97.23% |
| Pro-Dex, Inc. | 15.26 Million USD | 91.362% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 494.37 Thousand USD | -166.802% |
| Precision Optics Corporation, Inc. | 2.86 Million USD | 54.011% |
| QuidelOrtho Corporation | 577.8 Million USD | 99.772% |
| Repligen Corporation | 202.32 Million USD | 99.348% |
| Sanara MedTech Inc. | 4.71 Million USD | 72.04% |
| STAAR Surgical Company | 35.13 Million USD | 96.245% |
| Sharps Technology, Inc. | 1.7 Million USD | 22.826% |
| Utah Medical Products, Inc. | 9.58 Million USD | 86.235% |
| DENTSPLY SIRONA Inc. | 624 Million USD | 99.789% |
| Jin Medical International Ltd. | 5.05 Million USD | 73.897% |